Corona Remedies Quarterly Results for Trading Insights
In Mar 2026, Corona Remedies (CORONA) reported revenue ₹358 Cr and net profit ₹45 Cr — revenue +21.4% YoY. Also explore CORONA price movement history to track price trends across different timeframes.
CORONA Quarterly Results — Revenue, Profit & EPS Highlights
Corona Remedies latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with CORONA fair value to assess whether the stock is under or overvalued.
- Revenue of ₹358 Cr in Mar 2026 (-1.6% vs Sept 2025, +21.4% vs Mar 2025)
- Net Profit of ₹45 Cr in Mar 2026 (-13.5% vs Sept 2025, +40.6% vs Mar 2025)
- EBITDA of ₹66 Cr in Mar 2026 (-18.5% vs Sept 2025)
- Operating Margin of 18.0% in Mar 2026 (-4.0pp vs Sept 2025)
- Earnings Per Share of ₹7.41 in Mar 2026 (-13.3% vs Sept 2025)
Corona Remedies Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CORONA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 358 | 364 | 295 | 349 | 345 | -1.6% | 21.4% |
| Net Profit (₹ Cr) | 45 | 52 | 32 | 46 | 41 | - | - |
| EBITDA (₹ Cr) | 66 | 81 | 56 | 72 | 66 | - | - |
| EPS (₹) | 7.41 | 8.55 | 5.16 | 7.55 | 6.75 | - | - |
| Operating Margin (%) | 18.0% | 22.0% | 18.0% | 20.0% | 19.0% | - | - |
CORONA Share Price Trend — 1-Year Movement Across Quarterly Results
Corona Remedies 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit CORONA share price.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CORONA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Corona Remedies latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1878.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 144.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6760.5 | 2,860 | 689 | +7.1% | - | 24.1% | 260.3 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹149,048.00 Cr | 4405.7 | 3,219 | 591 | +11.3% | - | 18.4% | 251.2 |
|
Cipla
Mar 2026 |
₹116,053.85 Cr | 1432.1 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 208.5 |
|
Dr Reddys Laborator…
Mar 2026 |
₹108,804.06 Cr | 1336.7 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 504.4 |
All amounts in ₹ Crores